NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Forecast, Price & News $7.86 -0.28 (-3.44%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$7.78▼$8.3150-Day Range$7.86▼$9.7452-Week Range$7.78▼$15.09Volume288,274 shsAverage Volume388,230 shsMarket Capitalization$378.85 millionP/E RatioN/ADividend YieldN/APrice Target$27.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Nurix Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside249.2% Upside$27.44 Price TargetShort InterestBearish14.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.24Based on 2 Articles This WeekInsider TradingSelling Shares$43,898 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.55) to ($3.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector796th out of 972 stocksPharmaceutical Preparations Industry378th out of 449 stocks 3.4 Analyst's Opinion Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.44, Nurix Therapeutics has a forecasted upside of 249.2% from its current price of $7.86.Amount of Analyst CoverageNurix Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.32% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 20.2, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 12.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRIX. Previous Next 3.5 News and Social Media Coverage News SentimentNurix Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nurix Therapeutics this week, compared to 2 articles on an average week.Search Interest8 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows2 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,898.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Nurix Therapeutics is held by insiders.Percentage Held by Institutions90.36% of the stock of Nurix Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.55) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nurix Therapeutics (NASDAQ:NRIX) StockNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.Read More NRIX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRIX Stock News HeadlinesSeptember 28, 2023 | finance.yahoo.comNurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?September 20, 2023 | finance.yahoo.comNurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for InvestorsOctober 1, 2023 | Goldco (Ad)Biden's Digital Dollar NightmareOn July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late! September 15, 2023 | finance.yahoo.comWall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a BetSeptember 15, 2023 | finance.yahoo.comNurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should KnowSeptember 8, 2023 | finance.yahoo.comNurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?September 7, 2023 | msn.comNeedham Reiterates Nurix Therapeutics (NRIX) Buy RecommendationSeptember 7, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Nurix TherapeuticsOctober 1, 2023 | Goldco (Ad)Biden's Digital Dollar NightmareOn July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late! September 7, 2023 | marketwatch.comNurix Therapeutics Shares Rise Premarket on Seagen Collaboration >NRIXSeptember 7, 2023 | finance.yahoo.comNurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer TherapeuticsAugust 24, 2023 | finance.yahoo.comHere's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn SituationAugust 2, 2023 | finance.yahoo.comInsider Sell: Gwenn Hansen Sells 1,884 Shares of Nurix Therapeutics IncJuly 24, 2023 | markets.businessinsider.comAnalyst Cuts Nurix Therapeutics Price Target By 38%, Cites Lymphoma DataJuly 24, 2023 | msn.comHC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy RecommendationJuly 24, 2023 | finance.yahoo.comWall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to TradeJuly 18, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on Nurix Therapeutics (NRIX)July 17, 2023 | msn.comMorgan Stanley Maintains Nurix Therapeutics (NRIX) Equal-Weight RecommendationJuly 15, 2023 | finance.yahoo.comNurix Therapeutics Second Quarter 2023 Earnings: EPS Beats Expectations, Revenues LagJuly 14, 2023 | finanznachrichten.deNurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate UpdateJuly 13, 2023 | finance.yahoo.comNurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate UpdateJuly 11, 2023 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Earnings Expected to Grow: Should You Buy?June 29, 2023 | finance.yahoo.comNurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseJune 26, 2023 | benzinga.comOppenheimer Assumes Nurix Therapeutics at Outperform, Announces Price Target of $25June 15, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX), MoonLake Immunotherapeutics (MLTX) and Zoetis (ZTS)June 14, 2023 | finance.yahoo.comNurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma IndicationsMay 25, 2023 | finance.yahoo.comNurix Therapeutics (NASDAQ:NRIX) shareholders have earned a 25% return over the last yearSee More Headlines Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIX Company Calendar Last Earnings7/13/2023Today10/01/2023Next Earnings (Estimated)10/05/2023Fiscal Year End11/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NRIX CUSIPN/A CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees297Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.44 High Stock Price Forecast$36.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+249.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,360,000.00 Net Margins-258.37% Pretax Margin-258.37% Return on Equity-53.36% Return on Assets-39.44% Debt Debt-to-Equity RatioN/A Current Ratio4.01 Quick Ratio4.01 Sales & Book Value Annual Sales$38.63 million Price / Sales9.81 Cash FlowN/A Price / Cash FlowN/A Book Value$6.44 per share Price / Book1.22Miscellaneous Outstanding Shares48,200,000Free Float44,730,000Market Cap$378.85 million OptionableNot Optionable Beta1.63 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Arthur T. Sands M.D. (Age 61)Ph.D., CEO, Pres & Director Comp: $910.98kMr. Johannes Van Houte (Age 57)Chief Financial Officer Comp: $650.74kDr. Gwenn M. Hansen Ph.D. (Age 52)Chief Scientific Officer Comp: $661.19kDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardDr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardDr. Arthur Weiss M.D.Ph.D., Founder & Member of Scientific Advisory BoardRita KwongSr. Accounting Mang.Dr. Christine Ring J.D. (Age 58)Ph.D., Gen. Counsel & Sec. Mr. Eric C. Schlezinger J.D. (Age 56)Chief People Officer Dr. Jason Kantor Ph.D.Exec. VP of Fin. & Bus. StrategyMore ExecutivesKey CompetitorsMineralys TherapeuticsNASDAQ:MLYSLiquidiaNASDAQ:LQDAOculisNASDAQ:OCSMarinus PharmaceuticalsNASDAQ:MRNSProcaps GroupNASDAQ:PROCView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCSold 50,000 shares on 8/21/2023Ownership: 0.207%California State Teachers Retirement SystemBought 2,746 shares on 8/21/2023Ownership: 0.106%Nuveen Asset Management LLCSold 2,556 shares on 8/16/2023Ownership: 1.385%Public Employees Retirement System of OhioSold 5,493 shares on 8/15/2023Ownership: 0.178%Royal Bank of CanadaBought 3,078 shares on 8/15/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions NRIX Stock - Frequently Asked Questions Should I buy or sell Nurix Therapeutics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NRIX shares. View NRIX analyst ratings or view top-rated stocks. What is Nurix Therapeutics' stock price forecast for 2023? 9 brokerages have issued 1-year price objectives for Nurix Therapeutics' shares. Their NRIX share price forecasts range from $11.00 to $36.00. On average, they predict the company's share price to reach $27.44 in the next twelve months. This suggests a possible upside of 249.2% from the stock's current price. View analysts price targets for NRIX or view top-rated stocks among Wall Street analysts. How have NRIX shares performed in 2023? Nurix Therapeutics' stock was trading at $10.98 at the beginning of the year. Since then, NRIX shares have decreased by 28.4% and is now trading at $7.86. View the best growth stocks for 2023 here. When is Nurix Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 5th 2023. View our NRIX earnings forecast. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its earnings results on Thursday, July, 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. The company had revenue of $30.68 million for the quarter, compared to analyst estimates of $21.96 million. Nurix Therapeutics had a negative net margin of 258.37% and a negative trailing twelve-month return on equity of 53.36%. What ETF holds Nurix Therapeutics' stock ? ARK Genomic Revolution ETF holds 2,333,922 shares of NRIX stock, representing 0.94% of its portfolio. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR). When did Nurix Therapeutics IPO? (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. What is Nurix Therapeutics' stock symbol? Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX." How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nurix Therapeutics' stock price today? One share of NRIX stock can currently be purchased for approximately $7.86. How much money does Nurix Therapeutics make? Nurix Therapeutics (NASDAQ:NRIX) has a market capitalization of $378.85 million and generates $38.63 million in revenue each year. The company earns $-180,360,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. How many employees does Nurix Therapeutics have? The company employs 297 workers across the globe. How can I contact Nurix Therapeutics? The official website for the company is www.nurixtx.com. The company can be reached via phone at 415-660-5320 or via email at wolffe@wheelhouselsa.com. This page (NASDAQ:NRIX) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.